Novo Nordisk Potential Undervaluation in Obesity Drug Leader QSI Q1 2026 Earnings Narrowed Loss Surprises but Revenue Absence Weighs on Shares CoreWeave Analyst Ratings Mixed Views on AI Cloud Infrastructure Specialist